Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Japanese IP-TN Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02831569
Recruitment Status : Completed
First Posted : July 13, 2016
Results First Posted : July 20, 2018
Last Update Posted : July 20, 2018
Sponsor:
Collaborator:
SSP Co., Ltd.
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:

This is an open-label, single-group, multi-centre trial to confirm the safety and efficacy of loxoprofen sodium/methocarbamol ( IP-TN) when administered orally for 2 weeks to patients with low back pain, scapulohumeral periarthritis, or cervico-omo-brachial syndrome associated with muscle strain. More than 90 patients will be screened to enroll approximately 80 patients in the trial.

After giving written informed consent, patients will be enrolled in the trial. Patients who are considered eligible for the trial by the Investigator after consent and complete the trial procedures and assessments at Visit 1 will receive the trial medication and enter the open-label treatment period of 2 weeks. Patients who complete the open-label treatment period will enter the follow-up period of 1 week and complete the trial after confirmation at the last visit (or phone interview).


Condition or disease Intervention/treatment Phase
Pain Drug: Loxoprofen sodium Drug: Methocarbamol Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label, Single-group, Multicentre, Phase III Study to Confirm the Efficacy and Safety of IP-TN When Administered for 2 Weeks to Patients With Low Back Pain, Scapulohumeral Periarthritis, or Cervico-omo-brachial Syndrome Associated With Muscle Strain
Actual Study Start Date : July 27, 2016
Actual Primary Completion Date : October 19, 2016
Actual Study Completion Date : October 19, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Back Pain

Arm Intervention/treatment
Experimental: Loxoprofen sodium/methocarbamol FDC
fixed dose combination (FDC) tablets
Drug: Loxoprofen sodium
Drug: Methocarbamol



Primary Outcome Measures :
  1. Percentage of Patients With Drug-related Adverse Events [AEs] [ Time Frame: Up to 3 weeks. ]
    The outcome measure presents percentage of patients with drug-related AEs.


Secondary Outcome Measures :
  1. Assessment of Pain Due to Low Back Pain, Scapulohumeral Periarthritis or Cervico-omo-brachial Syndrome After 2 Weeks of Treatment [ Time Frame: Post 2 weeks. ]
    The outcome measure presents percentage of patients who showed "marked improvement" or "moderate improvement" in low back pain and/or scapulohumeral periarthritis and/or cervico-omo-brachial syndrome after 2 weeks of treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Male or female outpatients aged >=15 years at the time of giving consent.
  • Patients diagnosed with low back pain, scapulohumeral periarthritis, or cervico-omo-brachial syndrome prior to giving consent. Patients with cervico-omo-brachial syndrome must have the associated symptom of occipital pain.
  • No medical therapy for the target disease (low back pain, scapulohumeral periarthritis, or cervico-omo-brachial syndrome) for more than one week prior to Visit 1 (start day of treatment).
  • Patients who meet following criteria with examination conducted before the start of treatment at Visit 1(start day of treatment)

    • Based on patient interview, the evaluation site (low back, shoulder or neck) decided by investigator and visual analogue scales score of >=40 mm (in case there are some evaluation sites, investigators determine its evaluation sites to one site with the biggest of visual analogue scale score.
    • Visual analogue scales score of >=40 mm in one of pain symptoms (tenderness, listlessness, pain at rest, pain on motion, night-time pain, or limitation of motion) prior to the start of treatment.
    • Muscle strain at the evaluation site (low back, shoulder or neck) has been diagnosed by the Investigator based on patient interview and palpation.
  • Patients with pain symptoms at Visit 1 (start day of treatment) who are, in the Investigator's opinion, suitable for treatment with NSAIDs and muscle relaxants.
  • Signed and dated written informed consent in accordance with Good Clinical Practice and local legislation prior to admission to the trial. For minors (aged >=15 to <20 years), written informed consent must also be obtained from their legal representative.

Exclusion criteria:

  • Bronchial asthma at the time of giving consent For patients with allergic rhinitis or atopic disease, the absence of bronchial asthma must be confirmed and documented in the source data.
  • Treatment for oesophageal, gastric or duodenal ulcer or erosion within 4 weeks prior to giving consent
  • At Visit 1 (start day of treatment), patients with symptoms at the evaluation site due to injury, tumour, infection or rheumatoid arthritis, or those with obvious neurological (radicular) symptoms (e.g., hernia, etc.) or who may require surgery during the trial period
  • At Visit 1 (start day of treatment), cervical sprain (whiplash)
  • Patients who must carry out hazardous works such as working at high places or driving a car during the trial or those who are, in the Investigator's opinion, difficult to comply with the protocol.
  • Patients with cervico-omo-brachial syndrome whose headache is clearly different from the associated symptom of occipital pain or is indistinguishable from occipital pain
  • Patients on therapy for the target disease of this trial (low back pain, scapulohumeral periarthritis, or cervico-omo-brachial syndrome) at the time of giving consent or those having a plan to start a new therapy in the future. The therapy includes medical therapy, physical therapy and rehabilitation.
  • Using corticosteroids (oral, injection or suppository or topical use for pain relief) within 4 weeks prior to Visit 1 (start day of treatment)

    -- The use of inhaled corticosteroids for asthma and chronic obstructive pulmonary disease is allowed.

  • Patients who must use the prohibited medications or treatments during the trial period
  • Past or present alcohol or drug abuse
  • Past or present other clinically significant comorbidities (serious cardiac, renal, hepatic or haematologic disorders, psychiatric disorders, aspirin asthma, etc.) in the Investigator's judgment
  • Any documented or suspected allergy or hypersensitivity to the individual active ingredients of the trial medication, analgesics, NSAIDs, sulfa, cyclooxygenase inhibitors or lactose
  • Any documented active or suspected malignancy or history of malignancy within 5 years prior to Visit 1, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix
  • Premenopausal women (within 1 year since the last menstruation prior to giving consent) who are:

    • lactating or pregnant
    • having childbearing potential but not practicing adequate contraception or having no plan to use contraception continuously during the trial and refusing to take periodic pregnancy tests during the trial. Adequate contraceptive methods include tubal ligation, intrauterine device, oral contraceptive, complete abstinence, double-barrier methods and male partner's vasectomy.
  • Receiving any investigational product within 4 weeks prior to Visit 1 (start day of treatment) or having a plan to receive other investigational product during the trial.
  • Patients who are inappropriate as the subjects of this trial in the Investigator's opinion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02831569


Locations
Layout table for location information
Japan
Fukuwa Clinic
Tokyo, Chuo-ku, Japan, 103-0027
Tokyo-Eki Center-building Clinic
Tokyo, Chuo-ku, Japan, 103-0027
Shinjuku Res. Park Clinic, Tokyo, I.M.
Tokyo, Shinjyuku-ku, Japan, 169-0073
Sponsors and Collaborators
Boehringer Ingelheim
SSP Co., Ltd.
Investigators
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02831569    
Other Study ID Numbers: 1387.1
First Posted: July 13, 2016    Key Record Dates
Results First Posted: July 20, 2018
Last Update Posted: July 20, 2018
Last Verified: October 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Loxoprofen
Methocarbamol
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Muscle Relaxants, Central
Neuromuscular Agents